Horizon Discovery inks subscription-based licensing deal
Horizon Discovery has inked a subscription-based licensing deal for its biomanufacturing cell lines. The deal, the first of its type for the company and with an unnamed commercial partner, is worth a minimum of £500,000.
FTSE AIM All-Share
745.62
17:04 20/09/24
n/a
n/a
Horizon Discovery Group
184.50p
16:59 23/12/20
0.00%
0.00p
Pharmaceuticals & Biotechnology
22,415.97
16:49 20/09/24
-1.31%
-296.71
"We look forward to making further announcements in this area as Horizon continues its momentum as a key player in the bioproduction space," said chief executive Darrin Disley.
"This new announcement further validates our approach, with our Partner demonstrating their confidence by making a five year commitment via subscription model to the programme."